Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses the effectiveness of anti–PD-1 therapy in patients with recurrent head and neck cancer and the studies that might help predict who will benefit, how to combine agents, and ways to reduce long-term toxicity.
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.
For more information about this ongoing trial, visit clinicaltrials.gov
ClinicalTrials.gov ID: NCT03132636
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and monitor toxicities.
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses study findings on treating metastatic castration-sensitive prostate cancer, including results on radiotherapy and abiraterone (Abstract LBA5_PR).
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.
